Virbac Sa Stock Fundamentals

VIRP Stock  EUR 296.00  7.50  2.47%   
Virbac SA fundamentals help investors to digest information that contributes to Virbac SA's financial success or failures. It also enables traders to predict the movement of Virbac Stock. The fundamental analysis module provides a way to measure Virbac SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Virbac SA stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Virbac SA Company Return On Equity Analysis

Virbac SA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Virbac SA Return On Equity

    
  0.15  
Most of Virbac SA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virbac SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Virbac SA has a Return On Equity of 0.1542. This is 100.64% lower than that of the Healthcare sector and 92.83% lower than that of the Drug Manufacturers - Major industry. The return on equity for all France stocks is 149.74% lower than that of the firm.

Virbac SA Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Virbac SA's current stock value. Our valuation model uses many indicators to compare Virbac SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virbac SA competition to find correlations between indicators driving Virbac SA's intrinsic value. More Info.
Virbac SA is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about  0.59  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Virbac SA is roughly  1.69 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Virbac SA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Virbac SA's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Virbac Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virbac SA's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Virbac SA could also be used in its relative valuation, which is a method of valuing Virbac SA by comparing valuation metrics of similar companies.
Virbac SA is currently under evaluation in return on equity category among its peers.

Virbac Fundamentals

About Virbac SA Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Virbac SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virbac SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virbac SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. Virbac SA was founded in 1968 and is headquartered in Carros, France. VIRBAC operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 4893 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Virbac Stock

Virbac SA financial ratios help investors to determine whether Virbac Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.